• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

TG Therapeutics

brain
Posted inAutoimmune Diseases, Clinical Trials, Neuroscience

Ublyxi: Highly Effective Drug for Multiple Sclerosis

May 31, 2022September 8, 2022

Ublituximab is the third anti-CD20 therapy for multiple sclerosis and a worthy rival to Ocrevus and Kesimpta.

Kesimpta: Highly Effective New Drug for Multiple Sclerosis
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Kesimpta: Highly Effective New Drug for Multiple Sclerosis

June 4, 2021September 8, 2022

Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News